-
Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China
- August 10, 2026
- Posted by: Jessica Turner
- Category: Finance & accounting
No Comments
Collaboration to accelerate access to Vanflyta® for patients with newly diagnosed FLT3-ITD positive AMLSAN FRANCISCO and SUZHOU, China, Aug. 9, 2026 /PRNewswire/ — Innovent Biologics, Inc. (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement…
-
Second PIC/S GMP Certification | Mabwell Passes Brazilian GMP Inspection for Its Denosumab Injections
- August 10, 2026
- Posted by: Jessica Turner
- Category: Finance & accounting
SHANGHAI, Aug. 9, 2026 /PRNewswire/ — Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces that its wholly-owned subsidiary T-mab has successfully passed Brazilian Health Regulatory Agency’s (“ANVISA”) GMP on-site inspection for its…
-
Landis+Gyr Expands Edge Applications Ecosystem with Two New Digital Innovators to Power Next-Generation Intelligent Grid
- August 10, 2026
- Posted by: Jessica Turner
- Category: Competitive research
Future Grid and OTS join Landis+Gyr’s open Edge ecosystem to accelerate real-time distribution grid intelligence and innovation across Australia. SYDNEY, Aug. 10, 2026 /PRNewswire/ — Landis+Gyr (SIX: LAND) today expanded its Edge Application (App) Ecosystem in Australia, adding…